NATAP: CROI HIV & HIV Coverage

[Guest guest]

Subject: NATAP: CROI HIV & HIV Coverage NATAP CROI CoverageMajor topics receiving lots of attention at CROI were prevention/PrEP with tenofovir, with amazingly a 99% transmission prevention when adherence was excellent. There was a lot of attention to research on HIV cure/eradication. It is in the early days and way too soon to predict if & when major advances will or can be made, it remains to be seen if we can perhaps even find a functional cure meaning the virus remains but is held in check without HAART, but lots of resources are being devoted to this with a $12 million NIH grant plus research in industrt dedicated to this, so hopes are high. There was new data on the 2 new integrase inhibitors, new data on the new tenofovir prodrug GS7340 which it's hoped will be safer & more potent & hopefully patients on tenofovir could switch to it. There was new data on treating HCV coinfection with the 2 new HCV protease inhibitors boceprevir & telaprevir, and new data on PK interactions between HIV ARTs & boceprevir & TMC435, and interaction data on the new BMS HCV drug, their potent NS5A inhibitor with HIV ARTs, the phase 3 study with this drug has started. There is a lot of new from new studies of interest in complications, metabolics, heart disease, bone disease, etc. There will be much more comprehensive scientifically vigorous coverage & reporting on these topics from CROI by the NATAP team who covered the conference.CROI: 19th Conference on Retroviruses and

Opportunistic Infections

Seattle, WA

March 5 - 8, 2011CROI: Colonoscopy Spots Abnormalities in

60% of German HIV Group--and Cancer in 4% - written by Mark Mascolini - (03/9/11) CROI: Central Obesity Raises Neurocognitive Impairment Risk in US CHARTER Cohort - written by Mark Mascolini - (03/9/11) CROI: GS-7340

25 mg and 40 mg Demonstrate Greater Antiviral Activity Compared with TDF 300 mg in a 10-Day Monotherapy Study of HIV-1 Infected Patients - (03/9/11) CROI: DATA SHOW GILEAD'S QUAD REGIMEN FOR HIV NON-INFERIOR TO PROTEASEBASED REGIMEN AT 48 WEEKS IN SECOND PIVOTAL PHASE 3 STUDY - (03/9/11) CROI: Efficacy

and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF "Quad"

Compared to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Treatment Naive HIV-1 Infected Subjects - (03/9/11) CROI: Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ - (03/9/11)

CROI: Higher Death Rate With 350-499 CD4s vs 500+ in Virologic Responders - written by Mark Mascolini - (03/8/11) CROI: Low-Dose, Cell-Homing Tenofovir Prodrug Outdoes TDF in 10-Day Study - written by Mark Mascolini - (03/8/11) CROI: Not Taking Antiretrovirals Linked to 60% Higher Risk of Neurocognitive Decline in US - written by Mark Mascolini - (03/8/11) CROI: Kidney Renal Markers Signal Linked to Higher Tenofovir Plasma Levels - written by Mark Mascolini - (03/8/11) CROI: Higher Rate and Extent of Noncalcified Coronary Artery Plaque in HIV+ MACS Men - written by Mark Mascolini - (03/8/11) CROI: Quad Not Inferior to Efavirenz Combo at 48 Weeks in Phase 3 Trial - written by Mark Mascolini - (03/8/11) CROI: GILEAD'S QUAD SINGLE TABLET REGIMEN FOR HIV NON-INFERIOR TO ATRIPLA® IN PIVOTAL PHASE 3 STUDY - (03/8/11) CROI: The

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102 - (03/8/11) CROI: Dolutegravir ViiV Integrase Inhibitor phase 2b SPRING Study 96-Week Results in Treatment-Naives - (03/8/11) CROI: Poor Adherence May Explain FEM-PrEP

Failure to Find Protection From HIV With Truvada - written by Mark Mascolini - (03/7/11)

CROI: CD8 Activation and Naive CD4s Predict

CD4 Gains Through 10 to 15 Years of ART - written by Mark Mascolini - (03/7/11)

CROI: Black Women in US Have Doubled Risk of AIDS Death, Regardless of Adherence - written by Mark Mascolini - (03/7/11)

CROI: HIV Risk in US Black MSM Traced to Age Issues and

Care Barriers--Not to Risk Behavior - written by Mark Mascolini - (03/7/11)

CROI: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/11)

CROI: Rectal Tenofovir Gel Clears Hurdle of Safety and Acceptability Study - written by Mark Mascolini - (03/7/11)

CROI: Over Half of US HIV+ People in Care Are Sexually Active, But Most Take Precautions - written by Mark Mascolini - (03/7/11)

CROI: Studies Disagree on Danger in Detectable Viral Load Under 50 Copies - written by Mark Mascolini - (03/7/11)

CROI: Slower Virologic Response in Pregnant Women Starting ART in France - written by Mark Mascolini - (03/7/11)

CROI: Tenofovir

PrEP Reduces HIV Transmission Risk By Up To 99%: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/11)

CROI: CDC: HIV Rate in Young US MSM Twice Higher Than in Sub-Saharan Africa - written by Mark Mascolini - (03/7/11)

CROI: The Effect of CD4+ T-Cell Count on Cardiovascular Risk in Treated HIV Disease - (03/7/11) CROI: Suppression of Formation Threatens Delayed-Phase Bone Loss in Virologically Suppressed HIV-infected Individuals on Chronic ART - (03/7/11)HCVCROI: Assessment

of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r - (03/9/11)

CROI: GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results from the ELECTRON Trial - (03/7/11) CROI: PHARMACOKINETIC

INTERACTION BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1 PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR - (03/7/11) CROI: The

Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir, Efavirenz or Raltegravir in Healthy Volunteers - (03/7/11) CROI: Evaluation of NS3 Amino Acid Variants in a Phase 1b Study of GT 1 Infection with the HCV Protease Inhibitor, MK-5172 - (03/7/11) CROI: Influence of the HCV Protease Inhibitor

Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir - (03/7/11) CROI: Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR12 Interim Analysis - (03/7/11) CROI: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (03/7/11) CROI: HCV PI Boceprevir Lowers Levels of Three Key HIV PIs - written by Mark Mascolini - (03/7/11)